MedPath
HSA Product

AVOFER INJECTION 100MG/5ML

Product approved by Health Sciences Authority (SG)

Basic Information

AVOFER INJECTION 100MG/5ML

INJECTION

Regulatory Information

SIN16513P

June 16, 2022

Prescription Only

Therapeutic

INTRAVENOUS

August 10, 2023

June 3, 2025

XB03AC

Company Information

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**CONTRAINDICATIONS** The use of Avofer is contraindicated in the following conditions: - Hypersensitivity to iron sucrose, Avofer or to any of its excipients listed in section _List of excipients_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ - Anaemia not caused by iron deficiency - Evidence of iron overload or disturbances in utilisation of iron - Pregnancy first Trimester

Indication Information

**INDICATIONS** Avofer is indicated in the treatment of iron deficiency in the following indications: ➢ Where there is a clinical need for a rapid iron supply ➢ In patients who cannot tolerate oral iron therapy or who are non-compliant ➢ Where oral iron preparations are ineffective (e.g., in active inflammatory bowel disease). Avofer should only be administered where the indication is confirmed by appropriate investigations.

© Copyright 2025. All Rights Reserved by MedPath